Ownership history in Bellevue Group AG · 40 quarters on record
This page tracks every 13F SEC filing in which Bellevue Group AG reported a position in Abbott Laboratories (ABT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 1,316,915 | -161,648 | -10.9% | 3.13% | $165.0M | $124.66 |
| 2025 Q3 | REDUCED | 1,478,563 | -85,459 | -5.5% | 4.11% | $198.0M | $132.67 |
| 2025 Q2 | ADDED | 1,564,022 | +7,893 | +0.5% | 4.69% | $212.7M | $134.12 |
| 2025 Q1 | REDUCED | 1,556,129 | -132,531 | -7.8% | 4.63% | $206.4M | $130.21 |
| 2024 Q4 | REDUCED | 1,688,660 | -55,278 | -3.2% | 3.68% | $191.0M | $110.45 |
| 2024 Q3 | ADDED | 1,743,938 | +137,785 | +8.6% | 3.22% | $198.8M | $110.80 |
| 2024 Q2 | ADDED | 1,606,153 | +171,970 | +12.0% | 2.71% | $166.9M | $100.45 |
| 2024 Q1 | REDUCED | 1,434,183 | -101,473 | -6.6% | 2.49% | $163.0M | $109.34 |
| 2023 Q4 | REDUCED | 1,535,656 | -25,312 | -1.6% | 2.59% | $169.0M | $105.38 |
| 2023 Q3 | REDUCED | 1,560,968 | -85,533 | -5.2% | 2.44% | $151.2M | $92.21 |
As of 2025 Q4 — sorted by position size